Life Science Nation and YAFO Capital Announce ACCESS CHINA Forum (Spring 2021) – China Innovation Out-Licensing Event at Healthtech Partnering Week

February 25, 2021 ~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

In 2021, Life Science Nation (LSN) launched the digital Healthtech Partnering Week (HPW), which consists of the renowned digital Redefining Early Stage Investments (RESI) 3-day event, 4D Meets AI 2-day event, and the Longevity, Health & Innovation (LHI) 2-day event, and now introducing ACCESS CHINA 2-day forum. LSN introduced this new open-concept conference theme in order that other independent conferences could participate in the week-long event with access to LSN’s premier partnering capability, which matches early-stage companies with strategic investment and licensing partners. HPW welcomes global partnering events to leverage the LSN global partner network, providing an incredible value to all attendees.

YAFO Capital‘s ACCESS CHINA Forum is a quarterly corporate access event series between China and Western biopharma. It is a leading deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market, and for Chinese companies to enter the global market. ACCESS CHINA Spring Forum, which focuses on China biotech innovation and out-licensing opportunities, adds to the HPW momentum. The Forum creates a great opportunity for LSN’s buy-side global partner network of investors, pharma and corporate strategics seeking equity and licensing opportunities to look at elite technology assets coming out of Asia. The scientist-entrepreneurs and fundraising CEOs coming to HPW via ACCESS CHINA Forum will be able to make new connections with global partners that will help them transition from their regional markets to the global arena.

LSN welcomes any firm that has a standalone life science partnering event happening simultaneously with HPW to join forces. YAFO Capital’s ACCESS CHINA Forum is a great example of how we can work together and deliver elite technology assets to a broader investor and strategic partner audience. Our goal is to reach across borders and events to raise the tide of early-stage partnering and lift all fundraising efforts in order to advance the latest in life-saving technologies and healthcare treatments.

Free Webinar: Strategies for Successful Partnering

February 25, 2021 ~ Next Phase Admin ~ Leave a comment

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Life Science Nation (LSN) has recently held two free webinars outlining strategies for successful partnering. Whether new to LSN and our early stage partnering events, or a frequent participant seeking to optimize their experience, it’s our goal that you have access to learn how to use the platform well, so you can spend more time meeting investors and making deals.

Healthtech Partnering Week (HPW) launches March 15-19, and there’s still time to sign up and even apply for the Innovator’s Pitch Challenge (IPC) – applications are due tomorrow, February 26! If you’re an early stage fundraising executive unsure of what makes a powerful partnering platform, we invite you to watch our latest webinar on strategies for success partnering. Learn more and sign up at https://www.healthtechpartneringweek.com/.

Hot Mandate: Investment Firm Focuses on Data-Driven Healthcare/Biotech Companies, with specific Interest In Big Data, AI, Computational Health & Digital Health

February 19, 2021 ~ Next Phase Admin ~ Leave a comment

Founded 2013 and headquartered in San Francisco, the firm is investing from its most recent fund, which closed in early 2020 at $50 M. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large-scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot Mandate: Boston Based VC Focuses on Pre-Seed to Seed Stage Companies Using Frontier Technologies, Such As Machine-learning, AI & Computational Biotech

February 19, 2021 ~ Next Phase Admin ~ Leave a comment

A venture capital firm is founded in 2014 and headquartered in Boston, MA. The firm focuses on pre-seed and seed-stage investments, typically with an initial investment of $500K to $1M as part of the company’s first institutional funding. The firm prefers companies located in the US and Canada and is looking to make 5-10 new investments over the next 12 months.

The firm partners with entrepreneurs solving real-world problems with data and machine learning, focusing on applications of frontier technologies such as AI, computational biotech, connected sensors, AR/VR, and blockchain. Past investments include biomedical and genomics data analytics platforms, data and analysis tools for drug discovery, and related areas.

The firm desires experienced management teams with a vision for the future. The firm can take a board seat when they have specific expertise in the area, and does not have an equity target. Strong technical teams who have a deep understanding of their markets is desired, though they’re comfortable partnering with very early-stage (pre-product) companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot Mandate: California Based VC With Accelerator Program Invests In Tech-Driven Companies, Including Digital Health Technologies with AI or Big Data Components

February 19, 2021 ~ Next Phase Admin ~ Leave a comment

A venture capital firm based in California that invests in early-stage, technology-driven companies has recently started exploring life sciences/healthcare investment opportunities and is considering companies in various sectors. The initial check size of the firm can range from $500K – $2M. The firm also runs a program for those who has already participated in accelerator/incubator programs and want to further initial proofs of concept and early market validation to demonstrate long-term product/market fit, product roadmap, and business model. Companies that have already launched and want to expand go-to-market and reach profitability are welcome to participate in this program as well.

The firm invests in impactful, early-stage technology companies. Within life sciences and healthcare sectors, the firm is interested in medical devices (both 510k and PMA) with a strong data or hardware component and digital health technologies that leverage AI or big data analytics. The firm will not consider traditional therapeutics or diagnostics companies. In terms of disease area, the firm is opportunistic.

The firm can act as either lead or co-investor and is open to working with all kinds of management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

What Successful Partnering Really Looks Like: A Conversation with Neuro20 Technologies

February 18, 2021June 15, 2022 ~ Next Phase Admin ~ Leave a comment

By Rory McCann, Marketing Manager & Conference Producer, LSN

When fundraising executives seek out a successful partnering experience, so many define success with deals and checks. At Life Science Nation, we frequently hear success stories that do end with capital and funding, but many do not. Instead, these stories touch on the benefits of successful partnering that impact company growth and bottom line in other ways, often the details that are taken for granted when seeking strategic partners.

Neuro20 Technologies is one such success story. They attended their first digital RESI conference looking for capital but came out with so much more. Listen to their story, and sign up for Digital RESI JPM to learn more from the Neuro20 Technologies team and start your partnering success story!

Last Chance to Apply for the Innovator’s Pitch Challenge

February 18, 2021 ~ Next Phase Admin ~ Leave a comment

By Joey Wong, Investor Research Analyst, LSN

One of the most powerful features at Healthtech Partnering Week, March 15-19, is the Innovator’s Pitch Challenge. This is a valuable opportunity for fundraising CEOs to showcase their technologies to conference attendees and pitch live to a panel of active investors and industry experts. Each conference throughout the week will host its own Innovator’s Pitch Challenge to ensure best fit for sector and technology. Learn about each conference and determine the best fit for you!

Accepted companies will each be provided with a dedicated landing page on the conference’s Live Agenda, which will host a full-length pitch video, pitch deck, executive summary and any other supplementary materials that are submitted. Companies are also invited to participate in a live Q&A session, which will include a quick elevator pitch, followed by questions and insights from a panel of active investors and industry experts.

This is a valuable opportunity to not only boost exposure among all the conference attendees, but also connect and speak directly with active investors and industry experts in the space. If you are a fundraising CEO, you do not want to miss this opportunity!

The last day to apply for the Innovator’s Pitch Challenge is this Friday, February 19. Be sure to submit your applications before then!